EcoR1 Capital

**Signal Note: EcoR1 Capital initiates $605M position in ZYME** EcoR1's substantial entry suggests conviction in Zymeworks' clinical pipeline, likely driven by upcoming catalysts around its lead programs: azenosotide (ZW25, HER2-targeted bispecific) Phase 2 data in gastric cancer expected mid-2024, and potentially earlier readouts in breast cancer. The $605M position size (representing material conviction for a growth-stage crossover fund) indicates confidence in value inflection from these near-term milestones, though ZYME carries execution risk typical of clinical-stage bispecifics facing competitive HER2 landscapes.

# Signal Note: EcoR1 Capital Initiates $382M Position in ANAB EcoR1's substantial entry into AnaptysBio signals confidence in ANB030, the company's clinical-stage monoclonal antibody targeting IL-4 receptor alpha for moderate-to-severe atopic dermatitis, ahead of anticipated Phase 2b data expected in H1 2024. The $382M position (7.88M shares at ~$48.50/share) represents a meaningful crossover commitment from a growth-focused investor, suggesting conviction around competitive positioning in the crowded atopic dermatitis market dominated by dupilumab and emerging competitors. This timing aligns with ANAB's clinical inflection period and potential for rapid valuation re-rating on efficacy/safety readouts.

# Signal Note: EcoR1 Capital Initiates $290M Position in Jazz Pharmaceuticals EcoR1's substantial entry into JAZZ likely reflects conviction in the company's portfolio rebalancing post-Atara divestiture, with particular focus on sustained cash generation from established assets (Epidiolex in refractory epilepsy, Defitelio in hepatic VOD) and pipeline catalysts including ongoing Phase 3 data for JZP-458 (narcolepsy/idiopathic hypersomnia). The $290M position size signals confidence in near-term revenue stability and potential M&A or strategic optionality, though JAZZ's elevated debt load and recent trading volatility warrant monitoring for execution risk.

**Signal Note: EcoR1 Capital Initiates $199.6M Position in CRNX** EcoR1's entry into Crinetics signals confidence in the company's pipeline of oral selective somatostatin receptor agonists (SRAs), particularly macimorelin for adult growth hormone deficiency and paltusotide for acromegaly—both addressing large markets with limited oral treatment options and near-term catalysts (FDA decisions expected 2024-2025). The $199.6M commitment from a growth-stage crossover specialist suggests conviction that Crinetics' oral SRA platform can compete against established injectables and capture significant market share in endocrine disorders.

# Signal Note: EcoR1 Capital Initiates $77.9M Position in Centessa EcoR1's entry signals conviction in Centessa's pipeline depth across multiple modalities, particularly ZF874 (selectivity-enhanced GPCR agonist for metabolic disease) currently in Phase 2, and the company's recently completed $200M Series C positioning it through near-term catalysts. The $77.9M stake (~3.1% ownership) at a ~$2.5B valuation suggests EcoR1 sees asymmetric risk/reward ahead of potential Phase 2b readouts in obesity/diabetes indications expected 2025-2026. This contrasts with the stock's recent underperformance and de-SPAC skepticism, indicating potential institutional repositioning around clinical data maturation.

**SIGNAL NOTE: EcoR1 Capital initiates $72.9M position in CRSP** EcoR1's entry signals conviction in CRISPR's clinical pipeline momentum, likely driven by near-term catalysts around CTX001 (ex vivo CRISPR for sickle cell/beta-thalassemia) regulatory decisions or label expansion data expected in 2024-25. The $72.9M position size suggests a growth-stage crossover thesis on margin expansion as ex vivo therapies scale, though execution risk remains material given CRISPR's historical manufacturing challenges and competition from base-edited rivals (BEAM, VERV).

# Signal Note: EcoR1 Capital Initiates $67M Position in MBX Biosciences EcoR1's entry into MBX signals confidence in the company's pipeline, likely driven by clinical or regulatory momentum in their lead programs (MBX994 for NASH and MBX 8859 for obesity/diabetes). The $67M stake at ~2.1M shares suggests conviction in near-term catalysts, potentially including Phase 2b data readouts or partnerships that could de-risk the platform ahead of a broader biotech funding environment recovery.

# Signal Note: EcoR1 Capital Initiates $61.3M Position in Immunome EcoR1's entry signals confidence in Immunome's platform for discovering antibodies against difficult-to-drug targets, particularly in oncology and autoimmune disease. The $61.3M stake (substantial for EcoR1's typical check sizes) suggests conviction ahead of near-term catalysts, likely clinical data readouts or partnership announcements in their lead programs. This crossover investor's participation could attract additional institutional capital and de-risk upcoming milestones.

**Signal Note: EcoR1 Capital Entry into ORIC** EcoR1's $55M initiation suggests conviction in ORIC's pipeline timing, likely driven by upcoming catalysts for lead program ORIC-101 (GPRC120 agonist) in ulcerative colitis, which showed clinical benefit in Phase 2b and is advancing toward late-stage development. The crossover investor's entry at scale indicates belief in near-term value inflection from clinical readouts or partnership developments, though ORIC's commercial execution risk remains material given the crowded inflammatory bowel disease space.

# Signal Note: EcoR1 Capital Initiates $54.5M GLPGF Position EcoR1's entry into Galapagos suggests conviction in the company's pipeline recovery, likely anchored on filgotinib (Jyseleca) commercial traction in rheumatoid arthritis and upcoming data in IBD/ulcerative colitis where oral JAK1 selectivity could differentiate from competitors. The $54.5M stake size indicates confidence in near-term catalysts, potentially including 2024 revenue inflection or Phase 3 data readouts that could justify current valuation pressures from recent pipeline setbacks.

**Signal Note: EcoR1 Capital Initiates $49.8M Position in Xencor (XNCR)** EcoR1's new $49.8M stake in Xencor suggests conviction in the company's clinical-stage XmAb programs, particularly XmAb104 (IL-15 agonist for solid tumors, Phase 1b ongoing) and XmAb717 (TIM-3/CTLA-4 bispecific, Phase 1 in hematologic malignancies), which address validated immunotherapy modalities. As a growth-stage crossover fund, EcoR1's entry likely reflects confidence in near-term data readouts or licensing partnerships that could derisk the platform through 2024-2025.

# Signal Note: EcoR1 Capital Initiates $35.3M Position in BridgeBio EcoR1's new stake signals confidence in BridgeBio's late-stage pipeline, likely driven by upcoming catalysts in rare genetic diseases where the company has multiple Phase 2/3 programs (notably in osteogenesis imperfecta and other monogenic disorders). The $35.3M entry by a growth-stage crossover fund—which typically deploys ahead of inflection points—suggests conviction in near-term clinical or commercial inflection, potentially timed to anticipated data readouts or regulatory progression in 2024-2025.

# Signal Note: EcoR1 Capital Initiates $34.3M Position in ETON EcoR1's entry into Eton suggests conviction in the company's late-stage pipeline, likely driven by near-term catalysts around ETON-01 (ETO for autoimmune conditions) or other clinical readouts expected within 12-24 months. The $34.3M position size indicates meaningful conviction from a growth-focused investor with strong biotech selection track record, though this represents a modest stake requiring monitoring of additional institutional demand for validation.

EcoR1's $32.1M entry into CGON signals conviction in their lead candidate CG0070, an oncolytic adenovirus for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), ahead of Phase 3 efficacy readout expected in 2025. The crossover firm's growth-stage thesis likely hinges on NMIBC market size (~$1.8B annually) and limited competitive alternatives post-BCG failure, where CG0070 showed 47% complete response in Phase 2.

# Signal Note: EcoR1 Capital Initiates $28.7M Position in Zenas BioPharma EcoR1's entry into ZBIO signals conviction in the company's pipeline, likely driven by ZEN-797 (selective PI3K delta inhibitor) for autoimmune/inflammatory indications where EcoR1 has demonstrated thesis conviction. The $28.7M position size and growth-stage/crossover focus suggest near-term inflection catalysts, potentially including clinical data readouts or regulatory meetings within the next 12-18 months that could de-risk commercialization timelines.